Affichage 1 à 10 des 10 essais cliniques
|
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
|---|---|---|---|
|
(EN) A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MK-1026-011 (BELLWAVE-011) NCT06136559  Actif en recrutement
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
Leucémie lymphoïde chronique (LLC) |
Dr Samuel Nadeau Marie-Eve Fournier 418-724-3000 poste 8029 |
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821  Interruption temporaire
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Leucémie lymphoïde chronique (LLC) |
Dr Stéphane Doucet Chantal Gosselin 514-890-8000 poste 24892 |
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Interruption temporaire
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
Leucémie lymphoïde chronique (LLC) |
Dr Ghislain Cournoyer Yanick Sardin Laframboise 450-431-1020 poste 23429 |
|
(EN) A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN CLL-322 NCT04965493 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Leucémie lymphoïde chronique (LLC) |
Dre Sonia Skamene Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
|
(EN) A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006 NCT05458297 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Leucémie lymphoïde chronique (LLC) Lymphome non-hodgkinien (LNH) |
Dre Sarit Assouline Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
|
(EN) A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003 NCT04728893 Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Leucémie lymphoïde chronique (LLC) Lymphome non-hodgkinien (LNH) |
Dre Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Interruption temporaire
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Leucémie lymphoïde chronique (LLC) |
Dre Dominique Toupin Anick Champoux 819-346-1110 poste 12811 |
|
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy
MK-1026-010 (BELLWAVE-010) NCT05947851 Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Leucémie lymphoïde chronique (LLC) |
Dre Dominique Toupin Christine Lawson 819-346-1110 poste 12942 |
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Interruption temporaire
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Leucémie lymphoïde chronique (LLC) |
Dr Jean-François Larouche Philippe Nadeau 418-649-0252 poste 63115 |
|
(EN) A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Interruption temporaire
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Leucémie lymphoïde chronique (LLC) |
Dre Mélina Boutin Fanny Raquepas Trudel 450-466-5000 poste 3593 |
Groupe d'étude en oncologie du Québec